18 results about "LRP5" patented technology

Wnt signaling agonist compositions and methods for their use are provided. Wnt signaling agonists of the invention comprise a frizzled binding moiety, which is fused or conjugated to an LRP5 or LRP6 binding moiety.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5 / 6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.

The application discloses a kind of nanobody specifically binding LRP5 and / or 6 and its application.The nanobody has the ability of selectively targeting and binding LRP5 and / or LRP6, wherein part of the antibody can inhibit the interaction of LRP5 and / or LRP6 with Wnt protein, thereby effectively inhibiting Wnt signaling pathway.The nanobody provided by the application can not only specifically recognize the co-receptor LRP5 and / or LRP6 of Wnt signaling pathway, but also show higher binding affinity, and can be widely applied in the detection of LRP5 and / or LRP6 and related research fields.

Disclosed are a nanobody that specifically binds to LRP5 and / or LRP6 and a use thereof. The nanobody has the ability to selectively target and bind to LRP5 and / or LRP6. Some antibodies can inhibit the interaction between LRP5 and / or LRP6 and Wnt proteins, thereby effectively suppressing the Wnt signaling pathway. The provided nanobody specifically recognizes co-receptors LRP5 and / or LRP6 of the Wnt signaling pathway, exhibits high binding affinity, and can be widely applied to the field of detection and related research of LRP5 and / or LRP6.

To provide anti-LRP5 / 6 antibodies and methods of use.SOLUTION: The present invention provides anti-LRP5 / 6 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for treating diseases and disorders associated with Wnt pathway signaling. The present invention provides an isolated antibody, or an antigen-binding fragment thereof, that binds to one or more LRP5 or LRP6 receptor, comprising a sequence comprising: CDRH1, CDRH2 and CDRH3 sequences set forth for any of the antibodies of Table 1A; and / or CDRL1, CDRL2 and CDRL3 sequences set forth for any of the antibodies of Table 1A, or a variant of the antibody, or antigen-binding fragment thereof, comprising one or more amino acid modifications. The variant comprises less than 8 amino acid substitutions in the CDR sequences.SELECTED DRAWING: Figure 1

The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5 / 6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway and methods for their use.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

The invention discloses a shark source single-domain antibody targeting LRP6 and application of the shark source single-domain antibody. The single-domain antibody has an amino acid sequence as shown in SEQ ID NO: 1, shows nanomole-level high affinity to LRP6 protein, has an affinity constant KD value of 1.8 * 10 <-9 > M, shows excellent physical and chemical stability, has a thermal denaturation temperature as high as 75.6 DEG C, and can still retain 92% or more of binding activity after being incubated for 2 hours under a strong acidic condition. Meanwhile, the antibody has high specificity, and the cross reaction rate of the antibody with homologous protein LRP5 and homologous protein LDLR is lower than 4%. The invention also provides a composition for reducing hypertension, hyperglycemia and hyperlipidemia, which contains the single-domain antibody and a specific natural plant extract composite component. Experiments show that the composition can synergistically act on a plurality of pathological links of the metabolic syndrome, the symptoms of hyperglycemia, hyperlipidemia and hypertension are remarkably improved in an animal model, the effect is better than that of a single component and a traditional control drug, and a brand new multi-target treatment scheme is provided for prevention and treatment of the metabolic syndrome.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

To provide a method for treating gastrointestinal disorders using a modified WNT agonist and a modulator of the WNT signaling pathway. [Solution] In one embodiment, the present disclosure includes an engineered WNT agonist comprising (a) one or more binding domains that bind to one or more FZDs; and (b) one or more binding domains that bind to LRP5, LRP6, or both LRP5 and LRP6, wherein the polypeptide sequence has at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1 to 18, or a polypeptide sequence disclosed in any one of SEQ ID NOs: 1 to 25, Figure 2, Figure 6, Table 1, or Table 3, or a functional fragment or variant thereof, for example, its binding fragment, for example, a VHH domain, a heavy chain variable domain, or a light chain variable domain.

The application provides a method for constructing an Lrp5 A241T gene point mutation high bone mass mouse model, and belongs to the technical field of biotechnology.The method of the application is simpler than traditional Cre / loxP system operation, can realize precise gene modification, and has the advantages of short technical cycle and high efficiency.In addition, the mouse constructed by the application only has the target gene point mutation and does not carry other gene modifications, is consistent with the real mutation of the patient population, has the high bone mass characteristics through microCT and other methods, and has important application significance for subsequent exploration of high bone mass related mechanisms, research and development of related targeted therapeutic drugs or gene modification therapy for treating osteoporosis and other diseases, and expansion of the clinical application of LRP5 high bone mass mutations.

To provide a method for treating cancer.SOLUTION: The present invention provides a polypeptide capable of specifically binding to LRP5 and LRP6 for use in a method for treating and / or preventing a hyperproliferative disease, preferably cancer, wherein the method comprises administering the polypeptide capable of specifically binding to LRP5 and LRP6 in combination with a PD-1 antibody to a patient in need thereof.SELECTED DRAWING: None